<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">35118580</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Print">2193-8229</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>11</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Apr</Month>
            </PubDate>
          </JournalIssue>
          <Title>Infectious diseases and therapy</Title>
          <ISOAbbreviation>Infect Dis Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>GMMA Technology for the Development of Safe Vaccines: Meta-Analysis of Individual Patient Data to Assess the Safety Profile of Shigella sonnei 1790GAHB Vaccine in Healthy Adults, with Special Focus on Neutropenia.</ArticleTitle>
        <Pagination>
          <StartPage>757</StartPage>
          <EndPage>770</EndPage>
          <MedlinePgn>757-770</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-022-00596-x</ELocationID>
        <Abstract>
          <AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Shigellosis is a major health concern among children &lt; 5 years of age from developing countries, and there are no widely available vaccines to prevent it. The GMMA-based 1790GAHB investigational vaccine against Shigella sonnei was well tolerated and immunogenic in phase 1 and 2 studies conducted in healthy adults from Shigella endemic and non-endemic populations. Based on pooled data of five individual trials, we assessed the association between vaccine administration and the risk of neutropenia as well as the overall safety profile of 1790GAHB.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">The risk ratio (RR) of neutropenia was evaluated between participants receiving 1790GAHB (vaccinees) and active comparator/placebo (controls) using different ethnicity-specific absolute neutrophil count (ANC) thresholds established to define neutropenia. Safety was assessed in terms of solicited, unsolicited, and serious adverse events (AEs).</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 279 participants, 11 (5.5%) vaccinees and 4 (5.0%) controls had ANC below the appropriate threshold within 7 days post-vaccination. RR was 0.96 [95% confidence interval (CI) 0.54-1.70]. When neutrophil counts of participants of African descent were measured against an ethnicity non-specific threshold, they resulted in neutropenia episodes in 30 (37.0%) vaccinees and 16 (30.2%) controls, while only 2 (2.5%) vaccinees and 1 (1.9%) control had neutropenia when the ethnicity-specific threshold was applied. RRs were 0.98 (95% CI 0.75-1.28) and 1.30 (95% CI 0.1-17.6), respectively. Solicited and unsolicited AEs were slightly more frequent among vaccinees than controls. No serious AEs, other than neutropenia cases, were recorded in the vaccine group.</AbstractText>
          <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">By applying the appropriate threshold, no increased risk of neutropenia was identified in vaccinees compared with the controls. The frequency of neutropenia events varied drastically when ethnicity-appropriate thresholds were applied. This observation highlights the importance of selecting appropriate cut-off values according to the correct population reference. Overall, the 1790GAHB vaccine demonstrated an acceptable safety profile.</AbstractText>
          <CopyrightInformation>© 2022. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>De Ryck</LastName>
            <ForeName>Iris</ForeName>
            <Initials>I</Initials>
            <Identifier Source="ORCID">0000-0003-3044-1117</Identifier>
            <AffiliationInfo>
              <Affiliation>GSK, Siena, Italy. iris.x.de-ryck@gsk.com.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sarakinou</LastName>
            <ForeName>Eleanna</ForeName>
            <Initials>E</Initials>
            <AffiliationInfo>
              <Affiliation>GSK Vaccines Institute for Global Health, Via Fiorentina 1, 53100, Siena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Nakakana</LastName>
            <ForeName>Usman</ForeName>
            <Initials>U</Initials>
            <AffiliationInfo>
              <Affiliation>GSK Vaccines Institute for Global Health, Via Fiorentina 1, 53100, Siena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cilio</LastName>
            <ForeName>Giulia Luna</ForeName>
            <Initials>GL</Initials>
            <AffiliationInfo>
              <Affiliation>GSK, Siena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ndiaye</LastName>
            <ForeName>Augustin</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Takeda Pharmaceutical International AG, Zurich, Switzerland.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vella</LastName>
            <ForeName>Venanzio</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>GSK, Siena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Auerbach</LastName>
            <ForeName>Joachim</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>GSK Vaccines Institute for Global Health, Via Fiorentina 1, 53100, Siena, Italy.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Coalition for Epidemic Preparedness Innovations, London, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Granada</LastName>
            <ForeName>Juan-Paolo</ForeName>
            <Initials>JP</Initials>
            <AffiliationInfo>
              <Affiliation>Ferring Pharmaceuticals, Copenhagen, Denmark.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Conti</LastName>
            <ForeName>Valentino</ForeName>
            <Initials>V</Initials>
            <AffiliationInfo>
              <Affiliation>GSK Vaccines Institute for Global Health, Via Fiorentina 1, 53100, Siena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Podda</LastName>
            <ForeName>Audino</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>GSK Vaccines Institute for Global Health, Via Fiorentina 1, 53100, Siena, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>02</Month>
          <Day>03</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Infect Dis Ther</MedlineTA>
        <NlmUniqueID>101634499</NlmUniqueID>
        <ISSNLinking>2193-6382</ISSNLinking>
      </MedlineJournalInfo>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="ErratumIn">
          <RefSource>Infect Dis Ther. 2022 Apr 18;:</RefSource>
          <PMID Version="1">35435576</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">1790GAHB vaccine</Keyword>
        <Keyword MajorTopicYN="N">GMMA technology</Keyword>
        <Keyword MajorTopicYN="N">Neutropenia</Keyword>
        <Keyword MajorTopicYN="N">Safety profile</Keyword>
        <Keyword MajorTopicYN="N">Shigella sonnei</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>26</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>1</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>5</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>4</Day>
          <Hour>5</Hour>
          <Minute>55</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35118580</ArticleId>
        <ArticleId IdType="pmc">PMC8960504</ArticleId>
        <ArticleId IdType="doi">10.1007/s40121-022-00596-x</ArticleId>
        <ArticleId IdType="pii">10.1007/s40121-022-00596-x</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>GBD 2016 Diarrhoeal Disease Collaborators  Estimates of the global, regional, and national morbidity, mortality, and aetiologies of diarrhoea in 195 countries: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Infect Dis. 2018;18:1211–1228. doi: 10.1016/S1473-3099(18)30362-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(18)30362-1</ArticleId>
            <ArticleId IdType="pmc">PMC6202444</ArticleId>
            <ArticleId IdType="pubmed">30243583</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AKM. Shigellosis. Lancet. 2018;391:801–812. doi: 10.1016/s0140-6736(17)33296-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(17)33296-8</ArticleId>
            <ArticleId IdType="pubmed">29254859</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cohen D, Atsmon J, Artaud C, Meron-Sudai S, Gougeon M-L, Bialik A, et al.  Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study. Lancet Infect Dis. 2021;21:546–558. doi: 10.1016/S1473-3099(20)30488-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(20)30488-6</ArticleId>
            <ArticleId IdType="pubmed">33186516</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frenck RW, Jr, Baqar S, Alexander W, Dickey M, McNeal M, El-Khorazaty J, et al.  A Phase I trial to evaluate the safety and immunogenicity of WRSs2 and WRSs3; two live oral candidate vaccines against Shigella sonnei. Vaccine. 2018;36:4880–4889. doi: 10.1016/j.vaccine.2018.06.063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2018.06.063</ArticleId>
            <ArticleId IdType="pubmed">30037478</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Riddle MS, Kaminski RW, Di Paolo C, Porter CK, Gutierrez RL, Clarkson KA, et al.  Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella flexneri 2a administered to healthy adults: a single-blind, randomized phase I study. Clin Vaccine Immunol. 2016;23:908–917. doi: 10.1128/cvi.00224-16.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/cvi.00224-16</ArticleId>
            <ArticleId IdType="pmc">PMC5139601</ArticleId>
            <ArticleId IdType="pubmed">27581434</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van der Put RMF, Kim TH, Guerreiro C, Thouron F, Hoogerhout P, Sansonetti PJ, et al.  A synthetic carbohydrate conjugate vaccine candidate against shigellosis: improved bioconjugation and impact of alum on immunogenicity. Bioconjug Chem. 2016;27:883–892. doi: 10.1021/acs.bioconjchem.5b00617.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.bioconjchem.5b00617</ArticleId>
            <ArticleId IdType="pubmed">26918643</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kis Z, Shattock R, Shah N, Kontoravdi C. Emerging technologies for low-cost, rapid vaccine manufacture. Biotechnol J. 2019;14:e1800376. doi: 10.1002/biot.201800376.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/biot.201800376</ArticleId>
            <ArticleId IdType="pubmed">30537361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scholtz M, Duclos P. Immunization safety: a global priority. Bull World Health Organ. 2000;78:153–154.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2560674</ArticleId>
            <ArticleId IdType="pubmed">10743278</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Muturi-Kioi V, Lewis D, Launay O, Leroux-Roels G, Anemona A, Loulergue P, et al.  Neutropenia as an adverse event following vaccination: results from randomized clinical trials in healthy adults and systematic review. PLoS ONE. 2016;11:e0157385. doi: 10.1371/journal.pone.0157385.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0157385</ArticleId>
            <ArticleId IdType="pmc">PMC4974007</ArticleId>
            <ArticleId IdType="pubmed">27490698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Denic S, Narchi H, Al Mekaini LA, Al-Hammadi S, Al Jabri ON, Souid AK. Prevalence of neutropenia in children by nationality. BMC Hematol. 2016;16:15. doi: 10.1186/s12878-016-0054-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12878-016-0054-8</ArticleId>
            <ArticleId IdType="pmc">PMC4875641</ArticleId>
            <ArticleId IdType="pubmed">27213048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Micoli F, Alfini R, Di Benedetto R, Necchi F, Schiavo F, Mancini F, et al.  GMMA Is a versatile platform to design effective multivalent combination vaccines. Vaccines (Basel) 2020;8:540. doi: 10.3390/vaccines8030540.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/vaccines8030540</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Launay O, Lewis DJM, Anemona A, Loulergue P, Leahy J, Sciré AS, et al.  Safety profile and immunologic responses of a novel vaccine against Shigella sonnei administered intramuscularly, intradermally and intranasally: results from two parallel randomized phase 1 clinical studies in healthy adult volunteers in Europe. EBioMedicine. 2017;22:164–172. doi: 10.1016/j.ebiom.2017.07.013.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ebiom.2017.07.013</ArticleId>
            <ArticleId IdType="pmc">PMC5552227</ArticleId>
            <ArticleId IdType="pubmed">28735965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Launay O, Ndiaye AGW, Conti V, Loulergue P, Scire AS, Landre AM, et al.  Booster vaccination with GVGH Shigella sonnei 1790GAHB GMMA vaccine compared to single vaccination in unvaccinated healthy European adults: results from a phase 1 clinical trial. Front Immunol. 2019;10:335. doi: 10.3389/fimmu.2019.00335.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00335</ArticleId>
            <ArticleId IdType="pmc">PMC6418009</ArticleId>
            <ArticleId IdType="pubmed">30906291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Obiero CW, Ndiaye AGW, Sciré AS, Kaunyangi BM, Marchetti E, Gone AM, et al.  A phase 2a randomized study to evaluate the safety and immunogenicity of the 1790GAHB generalized modules for membrane antigen vaccine against Shigella sonnei administered intramuscularly to adults from a shigellosis-endemic country. Front Immunol. 2017;8:1884. doi: 10.3389/fimmu.2017.01884.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01884</ArticleId>
            <ArticleId IdType="pmc">PMC5763125</ArticleId>
            <ArticleId IdType="pubmed">29375556</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frenck RW, Conti V, Ferruzzi P, Ndiaye AGW, Parker S, McNeal MM, et al.  Efficacy, safety, and immunogenicity of the Shigella sonnei 1790GAHB GMMA candidate vaccine: results from a phase 2b randomized, placebo-controlled challenge study in adults. EClinicalMedicine. 2021;39:101076. doi: 10.1016/j.eclinm.2021.101076.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.eclinm.2021.101076</ArticleId>
            <ArticleId IdType="pmc">PMC8367798</ArticleId>
            <ArticleId IdType="pubmed">34430837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration Guidance for industry: toxicity grading scale for healthy adult and adolescent volunteers enrolled in preventive vaccine clinical trials. 2007 https://www.fda.gov/regulatory-information/search-fda-guidance-documents/toxicity-grading-scale-healthy-adult-and-adolescent-volunteers-enrolled-preventive-vaccine-clinical. Accessed 18 Aug 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>US Department of Health and Human Services NIoH, National Institute of Allergy and Infectious Diseases, Division of AIDS, Division of AIDS (DAIDS) Table for grading the severity of adult and pediatric adverse events, Corrected Version 2.1. 2017 https://rsc.niaid.nih.gov/sites/default/files/daidsgradingcorrectedv21.pdf. Accessed 18 Aug 2021.</Citation>
        </Reference>
        <Reference>
          <Citation>Karita E, Ketter N, Price MA, Kayitenkore K, Kaleebu P, Nanvubya A, et al.  CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa. PLoS ONE. 2009;4:e4401. doi: 10.1371/journal.pone.0004401.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0004401</ArticleId>
            <ArticleId IdType="pmc">PMC2632744</ArticleId>
            <ArticleId IdType="pubmed">19197365</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Koen A, Jose L, Madhi SA, Fix A, Cryz S, Groome MJ. Neutrophil counts in healthy South African infants: implications for enrollment and adverse event grading in clinical trials in an African setting. J Pediatr X. 2019;1:100005. doi: 10.1016/j.ympdx.2019.100005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ympdx.2019.100005</ArticleId>
            <ArticleId IdType="pmc">PMC7376988</ArticleId>
            <ArticleId IdType="pubmed">32734176</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
